This helps patients to maintain a youthful volume in their lips year after year
MBX 4291, dual GLP-1/GIP co-agonist prodrug designed for potential once-monthly dosing and improved tolerability in obesity Recent Highlights: In June 2026, MBX Biosciences announced data that demonstrated sustained benefit of its once-weekly Canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism
In STEP 1, the phase 3 trial that led to semaglutide's approval for obesity, participants lost about 15% of their body weight over a year
Yes, weight loss plateaus are common and expected as your body adapts
However, the results hold promise for informing future research and guidelines concerning perioperative care for patients using GLP-1 medication
GLP-1 is responsible for: Stimulating insulin production, which pulls sugar from the blood and carries it to the cells to be used as energy Regulating the appetite and hunger signals Decreasing the release of glucagon to lower blood sugar Controlling the rate at which the stomach empties after eating Medications like Semaglutide perform the same functions as GLP-1
